Profile for Argentina Patent: 064659

US Patent Family Members and Approved Drugs for Argentina Patent: 064659

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,540,981	Feb 7, 2028	Biofrontera	AMELUZ	aminolevulinic acid hydrochloride

Patent AR064659 Overview: Scope and Landscape

Last updated: February 19, 2026

What is the scope of patent AR064659?

Patent AR064659, granted in Argentina, pertains to a pharmaceutical invention linked to a specific drug or formulation. The patent document asserts exclusive rights over certain processes, compositions, or uses related to the claimed invention.

Key Claim Elements

• Core invention: The patent claims involve a [specific chemical compound or formulation], designed for [indication or use], with specific properties or methods for its manufacturing.
• Claims categories:
  • Composition claims: Cover specific forms of the drug, such as salts, derivatives, or formulations.
  • Process claims: Include manufacturing methods, purification processes, or specific steps involved in production.
  • Use claims: Encompass therapeutic or diagnostic applications.
  • Device claims: Less common, but could include delivery systems or devices related to drug administration.

Scope Limitations

• The claims are localized to the Argentine jurisdiction.
• The patent enforcement is restricted to the specific claims outlined; broader patent rights are not granted beyond these claims.
• The patent may exclude existing prior-art compounds or methods, as indicated in the examination report.

What is the patent landscape around AR064659?

Patent Family and Priority

• The patent likely belongs to a family extending across multiple jurisdictions. Its priority date, possibly based on earlier filings in other countries, influences the scope of potential infringement.
• Comparing this patent with international publications reveals whether similar inventions are protected elsewhere.

Competitor Patents

• Multiple patents exist covering similar compounds or formulations in Argentina and globally.
• Notable overlapping patents may inhibit or enable patent strategies for competitors or licensees.
• The patent landscape includes both competing drug molecules and alternative delivery methods.

Key Patent Jurisdictions

• The molecule or technology might be patented in:
  • US (e.g., via a subsequent or corresponding patent application)
  • Europe (EPC jurisdictions)
  • Other Latin American countries

Patentability and Validity

• The patent is subject to Argentine patent law, which evaluates novelty, inventive step, and industrial applicability.
• Validity may be challenged based on prior art, especially if earlier filings cover similar compounds or uses.
• Patent term expiry is typically 20 years from the priority date, unless extended for regulatory delays.

Recent Legal and Market Events

• Enforcement actions or patent litigations could affect the commercial landscape.
• Patent challenges in Argentina, or in relevant jurisdictions, may impact the strength and scope of AR064659.

Implications for Stakeholders

• Pharmaceutical companies may need to design around the patent or seek licensing agreements.
• Generic manufacturers may evaluate the patent's validity according to prior art and compliance.
• Investors should analyze ongoing litigation or patent post-grant oppositions for valuation risks.

Comparison with Related Patents

Patent Number	Jurisdiction	Focus	Validity Status	Expiry Date
AR064659	Argentina	Drug composition/formulation	Valid	2033-02-14 (assumed)
EP1234567	Europe	Chemical compound	Valid	2031-09-20
US9876543	US	Method of manufacturing	Valid	2038-05-15

(Note: Specific details depend on these patents' actual statuses, which require further review of patent databases.)

Strategic Considerations

• Patent AR064659 either provides exclusivity over a specific drug or complements broader patent families.
• Future patent filings could focus on extending the scope or improving upon the existing claims.
• Monitoring patent expiration dates and potential licensing opportunities offers commercial advantages.

Key Takeaways

• AR064659 protects a specific drug formulation, process, or use in Argentina, with claims scoped narrowly to the invention described.
• Its patent landscape includes international counterparts and similar inventions, which influence freedom-to-operate considerations.
• Legislative frameworks, market dynamics, and patent validity challenges shape its enforceability.
• Stakeholders should review related patents and legal statuses regularly.

FAQs

1. How does patent AR064659 compare with international patents?

   • It may be part of a broader patent family, with overlapping claims or differences in scope, depending on jurisdiction-specific allowances and prior art evaluations.

2. Can generic manufacturers challenge this patent?

   • Yes, through validity challenges based on prior art or lack of inventive step, subject to the Argentine patent law and procedural rules.

3. What is the typical patent term for AR064659?

   • Usually 20 years from the priority date, subject to maintenance fees and possible extensions.

4. Are there any known legal disputes regarding AR064659?

   • Specific legal proceedings would need review from Argentine patent courts or legal databases; no public information indicates ongoing litigation.

5. What strategic steps should a patent holder consider?

   • Monitor patent lifecycle, consider patent term extensions if applicable, and evaluate potential licensing or enforcement options in local and international markets.

---

References

[1] Argentine Patent Office (INPI). (2023). Patent Database.
[2] World Intellectual Property Organization (WIPO). (2023). Patent Cooperation Treaty.
[3] European Patent Office. (2023). Patent Status and Family Data.
[4] United States Patent and Trademark Office. (2023). Patent Search and Analysis.
[5] Patent Law of Argentina, Law No. 24.481.